Biolegend, 124610, PE anti-mouse CD40 Antibody, 100μg

CD40 is a 48 kD type I transmembrane glycoprotein also known as Bp50. It is a member of the tumor necrosis factor receptor (TNFR) superfamily and is expressed on B cells, basal epithelial cells, macrophages, follicular dendritic cells, endothelial cells, and a subset of CD34 + hematopoietic progenitors. CD40 regulates B cell development/maturation, Ig isotype switching and, in combination with other signals such as IL-4, protects B cells from surface Ig-induced apoptosis and promotes proliferation. Interaction of CD40 with its ligand CD154 (gp39), which is expressed on activated T cells, is important in costimulation and immune regulation.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Recombinant mouse CD40 protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124627 &124628) with a low endotoxin limit (Endotoxin < 0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Hasbold J, et al. 1994. Eur. J. Immunol. 24:1835. Bourgeois C, et al. 2002. Science 297:2060.
Product Citations: Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed Liu J, et al. 2019. Immunity. 50:600. PubMed Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed Ho HM, et al. 2022. Pharmaceutics. 14:. PubMed Hao H, et al. 2023. Nat Biomed Eng. . PubMed Li Y, et al. 2023. Front Cell Infect Microbiol. 13:1117230. PubMed van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed Hsieh MS, et al. 2023. NPJ Vaccines. 8:82. PubMed Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed Nocera D, et al. 2016. J Immunol. 196: 2860 - 2869. PubMed Carlsson J, et al. 2015. PLoS One. 10: 0143741. PubMed Romain Bouziat et al. 2018. Cell host & microbe. 24(5):677-688 . PubMed Kiritsy MC, et al. 2021. Elife. 10:. PubMed Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed Tyagi AM et al. 2018. Immunity. 49(6):1116-1131 . PubMed Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed She L, et al. 2021. JCI Insight. 6:e143509. PubMed Jing L, et al. 2022. Front Immunol. 13:864995. PubMed Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed Varol D et al. 2017. Immunity. 46(6):1030-1044 . PubMed Ding M, et al. 2019. Exp Ther Med. 18:2323. PubMed Ozeri E, et al. 2012. J Immunol. 189:146. PubMed Wang J, et al. 2017. Mol Med Rep. 16:8434. PubMed Ise W, et al. 2018. Immunity. 48:702. PubMed Mulas F, et al. 2020. Cell Mol Immunol. . PubMed Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed Wang Y, et al. 2009. Clin Cancer Res. 5.417361111. PubMed Qian J, et al. 2021. Int J Mol Sci. 22:. PubMed Mao L, et al. 2022. Front Immunol. 13:833418. PubMed Sun L, et al. 2015. Sci Rep. 5: 14871. PubMed Morris AB, et al. 2020. Immunity. 52(1):136-150.e6.. PubMed Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed Gubin MM, et al. 2018. Cell. 175:1014. PubMed Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed Dong X, et al. 2022. Front Immunol. 13:896472. PubMed Pizzurro GA, et al. 2021. Cancers (Basel). 13:. PubMed Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed Pradhan K, et al. 2021. J Immunol. 206:2980. PubMed Kadir NA, et al. 2020. Pathogens. 9:00. PubMed Lee C, et al. 2011. J Leukoc Biol. 90:911. PubMed Liang Z, et al. 2017. Autophagy. 14:505. PubMed Wallner S, et al. 2013. PLoS One. 8:65178. PubMed Koyama M et al. 2019. Immunity. 51(5):885-898 . PubMed Zhang H, et al. 2020. Cell Reports. 29(9):2659-2671.e6.. PubMed Lalor R, et al. 2019. Nutrients. 11. PubMed Chen S, et al. 2018. Nat Commun. 9:5298. PubMed Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed Liang Z, et al. 2022. iScience. 25:105233. PubMed Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed Lin YC, et al. 2020. Mol Med Rep. 22:4909. PubMed Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
RRID: AB_1134084 (BioLegend Cat. No. 124609) AB_1134075 (BioLegend Cat. No. 124610)
Structure: 48 kD type I transmembrane glycoprotein, a member of the tumor necrosis factor receptor (TNFR) superfamily.
Distribution: Expressed on B lymphocytes and other antigen-presenting cells, such as macrophages, follicular dendritic cells, etc.
Function: Regulates B cell growth and differentiation and Ig isotype switching. Interaction of CD40 with its ligand, CD154, on activated T cells is important for immune response.
Ligand/Receptor: CD154 on T cells
Cell Type: Antigen-presenting cells, B cells, Dendritic cells, Macrophages
Biology Area: Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family: CD Molecules
Antigen References: 1. Grewal IS, et al. 1998. Annu Rev Immunol 16:111.
Gene ID: 21939
UniProt: View information about CD40 on UniProt.org
Clone: 3/23
Regulatory Status: RUO
Other Names: Bp50, TNFRSF5
Isotype: Rat IgG2a, κ
Q: What type of PE do you use in your conjugates?
A: We use R-PE in our conjugates.